Telomir Pharmaceuticals Inc. has seen its stock price surge 53% after announcing promising in vitro data for its lead drug candidate, Telomir-1, a potential first-in-class epigenetic therapy for cancer, aging, and age-related diseases.

Telomir Pharmaceuticals Inc. has reported promising in vitro results for its lead drug candidate, Telomir-1, which has the potential to inhibit cancer growth and address age-related diseases.

Telomir Pharmaceuticals’ stock surges after promising results from its Progeria treatment trials, highlighting the company’s potential to revolutionize treatment for age-related diseases.

Telomir Pharmaceuticals’ stock price surged 150% after promising preclinical data on its cancer treatment Telomir-1, but experts question whether this is a genuine breakthrough or a speculative bubble.

Telomir Pharmaceuticals Inc. has secured $3 million in equity financing to advance its Investigational New Drug (IND) submission for its rare disease treatment, Telomir-1.